Ryan Scott

Articles

Mohty Shares Key Takeaways From the 50th Annual EBMT Meeting, Highlighting Advances in GVHD

May 9th 2024

Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EBMT Meeting, focusing on ongoing efforts within the GVHD treatment arena.

Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer

May 9th 2024

Adjuvant treatment with pembrolizumab plus chemotherapy did not improve DFS vs placebo plus chemotherapy in high-risk endometrial cancer.

Action is Key to Continue to Break Down Barriers for Equitable Cancer Care

May 8th 2024

Experts from the University of Wisconsin Health discuss ongoing barriers to equitable cancer care and ways to drive change.

Awareness and Early Detection Remain Key Issues in Ovarian Cancer

May 8th 2024

Vaidehi Mujumdar, MD, discusses updates in ovarian cancer for 2024 World Ovarian Cancer Day.

Enfortumab Vedotin/Pembrolizumab vs Nivolumab/Chemo: Selecting a Frontline Therapy for Advanced Urothelial Carcinoma

May 7th 2024

Thomas Flaig, MD, discusses how enfortumab vedotin/pembrolizumab and nivolumab/chemotherapy fit in the frontline treatment of advanced urothelial carcinoma.

UW Health Experts Underscore Value of Continuous Mentorship to Champion Women in Oncology

May 6th 2024

UW Health experts advocate for more women in leadership positions and discuss the need to cultivate diversity to reduce disparities in cancer care.

Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML

May 6th 2024

Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.

FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

May 6th 2024

The FDA has accepted a biologics license application for subcutaneous nivolumab for adult patients eligible for approved solid tumor nivolumab indications.

Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection

May 3rd 2024

Rebecca Klisovic, MD, discusses 4 case studies of patients who presented with varying types of myelofibrosis and the appropriate treatment avenues for each patient.

Eftilagimod Alpha–Based Triplet Is Well Tolerated, Generates Responses in Soft Tissue Sarcoma

May 2nd 2024

Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma.

Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer

May 1st 2024

Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.

Expansion of Luspatercept Indication Underscores Evolving Treatment Landscape for Low-Risk MDS

April 30th 2024

Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.

PROs Underscore Utility of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

April 29th 2024

Gottfried E. Konecny, MD, discusses PRO data for mirvetuximab soravtansine derived from the phase 3 MIRASOL trial.

Understanding Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

April 27th 2024

Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.

Toxicities Hinder Potential Efficacy of Ceritinib/Trametinib in Pretreated Advanced Melanoma

April 26th 2024

Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC

April 26th 2024

Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.

Fruquintinib Receives Positive CHMP Opinion for Previously Treated mCRC

April 26th 2024

CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.

Navigating Personalized Approaches With Radiation Therapy for Early-Stage Breast Cancer

April 26th 2024

Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy in early-stage breast cancer.

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

April 25th 2024

Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.

Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer

April 24th 2024

Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.